Clinical trials: Respiratory Disorder
Seasonal Allergic Rhinitis
Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis
The trial will be conducted as a prospective, randomized, multinational, multicenter, double-blind, placebo and active controlled trial in 4 parallel-groups of patients suffering from seasonal allergic rhinitis.
- Trial name
- NCT05311475
- Testing
- Mometasone, Azelastine
- Where
- 28 sites in Bulgaria, Germany and 2 more
- Volunteers
- 669 people
- Sponsor
- Sandoz
Chronic Obstructive Pulmonary Disease, COPD
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.
- Trial name
- NCT01708057
- Testing
- AZD8683, Tiotropium
- Where
- 6 sites in Poland, Sweden
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Lung Cancer
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005872
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Asthma
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation.
- Trial name
- NCT03562195
- Testing
- Mepolizumab 100 milligrams, Salbutamol
- Where
- 42 sites in China
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days…
- Trial name
- NCT00266812
- Testing
- Temozolomide and radiotherapy, Whole brain radiotherapy
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Pulmonary
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as…
- Trial name
- RIALTO (NCT02759419)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 9 sites in France, South Korea
- Volunteers
- 18 people
- Sponsor
- Bayer
House Dust Mite Allergy, Rhinoconjunctivitis
ToleroMune House Dust Mite Follow on Study
House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is associated with poorer lung function, greater…
- Trial name
- NCT01923792
- Volunteers
- 105 people
- Sponsor
- Circassia Limited
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This study is a global multicenter randomized factorial double-blind, placebo-controlled trial designed to evaluate (i) efficacy and safety of nitazoxanide 600 mg administered orally twice daily for five days compared to a…
- Trial name
- NCT01610245
- Testing
- Nitazoxanide, Oseltamivir
- Where
- 167 sites in United States, Australia and 3 more
- Volunteers
- 1,941 people
- Sponsor
- Romark Laboratories L.C.
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
Lung Neoplasm Malignant
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or…
- Trial name
- NCT06788912
- Testing
- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine
- Where
- 39 sites in United States, Chile and 7 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Obstructive Sleep Apnea
LTR for Treatment of Obstructive Sleep Apnea
Study of tongue implant for treatment of obstructive sleep apnea
- Trial name
- NCT03066765
- Testing
- Linguaflex Tongue Retractor
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Linguaflex, Inc.
Cough
A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HS-10383 in Chinese adult subjects with…
- Trial name
- NCT06246565
- Testing
- HS-10383
- Volunteers
- 276 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Asthma, Bronchiectasis
A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
The primary objective is to evaluate whether DAS181 is safe in subjects with well-controlled asthma or bronchiectasis.
- Trial name
- DAS181 (NCT01113034)
- Testing
- DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ansun Biopharma, Inc.
Chronic Obstructive Pulmonary Disease
A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients
This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily [BID]) and a placebo control in moderate…
- Trial name
- NCT02272634
- Testing
- YPL-001 80 mg, YPL-001 160 mg
- Where
- 4 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Asthma
Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices
This study assessed the efficacy, safety, tolerability, and pharmacokinetics of two different formulations of indacaterol, one administered via the Concept1 device and one administered via the Simoon device.
- Trial name
- NCT01012739
- Testing
- Indacaterol 150 μg via the Concept1 dry-powder inhaler, Indacaterol 60 μg via the Simoon dry-powder inhaler, Indacaterol 120 μg via the Simoon dry-powder inhaler
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320)…
- Trial name
- NCT02571777
- Testing
- QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320
- Where
- 403 sites in Argentina, Austria and 39 more
- Volunteers
- 3,092 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasms
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
The purpose of study to determine the activity of CI 1033 against tumors in patients with advanced or metastatic NSCLC who have failed prior platinum-based combination chemotherapy.
- Trial name
- NCT00050830
- Testing
- CI 1033
- Where
- 57 sites in United States, Canada and 6 more
- Volunteers
- 163 people
- Sponsor
- Pfizer
Asthma
Bronchial Ablation for Treatment of Asthma (BATA) Trial
To evaluate the safety and efficacy of a bronchial radiofrequency ablation system (SyMap Medical (Suzhou) Ltd) in a population of subjects with severe asthma who are still symptomatic despite being managed on high-dose Inhaled…
- Trial name
- BATA (NCT03765307)
- Testing
- SyMap Bronchial Ablation System, Boston Scientific Alair System
- Where
- 15 sites in China
- Volunteers
- 160 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
COPD
A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT02040792
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 355 people
- Sponsor
- Mylan Inc.
Chronic Obstructive Pulmonary Disease
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
Primary Objective: To evaluate the pharmacokinetics of Tiotropium Bromide Inhalation Powder (Strength:18 mcg; manufactured by Chia Tai Tianqing Pharmaceutical Group Co.
- Trial name
- NCT06326671
- Testing
- Tiotropium Bromide Inhalation Powder, Spiriva HandiHaler
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.